As advised via PHARMAC Tender Results of 30 April 2019 there is to be a change in the listing and future sole supply of Levomepromazine hydrochloride injection 25 mg/ml 1ml 10

New listing from 1 November 2019

Nozinan Injection 25 mg /ml 1 ml 10 ampoules                                                              Pharmacode 549142                      Schedule price $33.50

Incumbent brand

Levomepromazine Wockhardt Inj 25 mg / ml 1 ml 10 ampoules                                           Pharmacode 2501902                  Schedule price $47.89

HSS (Hospital Supply Status) & CSS (Community Supply Status) commences 1 April 2020.

Brand switch fee for Community Pharmacy not advised.

As of the date of this notification ProPharma / PWR cannot accept Levomepromazine Wockhardt Inj 25 mg for credit under any circumstances.

From 1 November 2019 community pharmacies dispensing Levomepromazine hydrochloride inj 25 mg will need to support patients changing to the new brand and manage stock during the transition.

We would recommend you continue to purchase the incumbent and we will change automatically as existing stocks are exhausted.

Benefit of staying with incumbent while stock remains available are minimal, but every cent counts:-

Levomepromazine Inj : – Per pack of  10. Therefore 1 x @ $47.89 x 3% = $1.4367 plus $0.253 (pack fee) giving you $1.6897

Compared to $33.50 x 3% = $1.0050 plus $0.253 (pack fee) giving you $1.2580

You MUST manage your stock to avoid being caught with stock at the time sole supply commences 1 April 2020. Failure to do so may prove very costly.

Once again we need your support to ensure stock in the supply chain moves through, to effectively ensure no losses are incurred by – supplier, wholesaler and pharmacy.

ProPharma / PWR will make a commercial decision in relation to stock holding which will potentially mean a change for pharmacy and patient. Unfortunately with the PHARMAC decision to have both new and incumbent products listed and fully funded until the commencement of the sole supply 1 April 2020 we need to act in the best interest of the company, pharmacy and patient. The patient will need to change, however wholesalers and pharmacy do not need to experience potential losses during the transition period.

Together we can make this a seamless and painless transition.

We thank you in anticipation of your ongoing support.


About The Author